z-logo
Premium
Efficacy and safety of dupilumab in atopic dermatitis in elderly patients: a retrospective study
Author(s) -
Napolitano M.,
Fabbrocini G.,
Scalvenzi M.,
Blasio C.,
Stingeni L.,
Patruno C.
Publication year - 2020
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/ced.14260
Subject(s) - dupilumab , atopic dermatitis , medicine , polypharmacy , retrospective cohort study , observational study , dermatology , monoclonal , monoclonal antibody , immunology , antibody
Summary Atopic dermatitis (AD) is a common inflammatory skin disease with high prevalence in both children (15–30%) and adults (2–10%), but limited data are available for older people. Elderly patients form a challenging group, as multiple comorbidities, associated polypharmacy and failures with previous treatments are common. We performed a retrospective observational study on elderly (≥ 65 years) patients treated with dupilumab, monoclonal antibody to the shared alpha subunit of the interleukin‐4 and ‐13 receptor approved for the treatment of moderate‐to‐severe AD in adults.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here